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Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis
stillremainsdismal,withamediansurvivalof15months.Theincorporationofbevacizumabinthestandardtreatmentofrelapsed
glioblastoma has been a signiﬁcant step towards combining targeted agents with chemotherapy, and there is an increasing number
of new antiangiogenic agents in various stages of development, that are being tested both in relapsed and newly diagnosed disease,
alone or in combination with standard treatment. The relatively favorable toxicity proﬁle for most of them presents an advantage,
but several concerns arise regarding their actual eﬃcacy on the clinical level and the most eﬃcient schedule of administration for
each of them, as their molecular targets and patterns of action may vary signiﬁcantly. This may lead to future modiﬁcations of the
current rational of administering these agents concomitantly with initial chemotherapy or maintenance treatment.
1.Introduction
Glioblastoma is the most common malignant glioma in
adults and, in spite of its relatively low incidence in the
general population, it is a disease with extremely high mor-
bidity and mortality. Practically all patients eventually die of
a disease-related complication. The current standard of care
includes maximum surgical resection and radiotherapy with
concomitant temozolomide followed by adjuvant temozolo-
mide as initially described by Stupp et al. in 2005 [1]. Despite
the improvement in survival observed in this trial, the
majority of patients survive less than 2 years from diagnosis,
while less than 5% will be alive in 5 years, experiencing
signiﬁcant deterioration in their quality of life and multiple
debilitating symptoms. Therefore, the demand for more
eﬀective treatment remains imperative and the introduction
of new agents in clinical trials continuously produces new
data that will hopefully lead to better treatment results in the
near future.
This short paper will focus on bevacizumab and the
novel antiangiogenic agents cediranib, cilengitide, sunitinib,
sorafenib, vandetanib, aﬂibercept, ABT-510 (thrombospon-
din-1) XL184, and tandutinib that are currently in vari-
ous stages of clinical development both on recurrent and
untreated glioblastoma.
2.Targeting Angiogenesis inGlioblastoma
Inhibition of angiogenesis has been a long-standing ther-
apeutic target, as gliomas are highly vascular tumors and
several researchers have demonstrated the signiﬁcance of the
vascular endothelial growth factor (VEGF) family and its
receptors in the angiogenesis and proliferation of the glioma
cells [2, 3]. The rapid growth that characterizes gliomas
results to regional hypoxia, which stimulates VEGF secretion
via the HIF-1a activation [4]. VEGF-A binds to VEGFR-2
in the vascular wall and promotes endothelial cell migration
and proliferation, leading to formation of new vessels and
recruitment of bone marrow-derived endothelial precursor
cells in the circulation, that are directly incorporated into
the tumor vessels [5, 6]. These vessels have several abnormal
features as large diameter, tortuous route, decreased pericyte
coverage, and increased thickness of basement membrane.
The blood ﬂow and permeability are increased, and the
transport properties are altered. The tumor environment
develops areas of hypoxia, increased interstitial pressure, and2 Chemotherapy Research and Practice
necrosis, features that are diagnostic marks of glioblastoma.
The change of permeability aﬀects the blood-brain barrier
and contributes to the vasogenic cerebral edema formation
that is usually present on diagnosis [7].
Angiogenesis is a complex, interactive procedure involv-
ing several molecular pathways. VEGF plays a key role and
besides hypoxia it can be activated by many other factors
as acidosis, oncogenes and tumor suppressor genes (kit
and p53), cytokines [8] (EGF, FGF-b, PDGF), and signal
transductionpathwaysasthePI3k/Akt andRas/MAPK.Also,
various molecules can activate angiogenesis under certain
conditions, like the angiopoietin-1/angiopoietin-2/tie-2 sig-
naling pathway, the insulin-like growth factor, hepatocyte
growth factor, interleukins, tumor necrosis factor-α,a n d
the cyclooxygenase-2 [9, 10]. Cell surface integrins ανβ3
and ανβ5, matrix metalloproteinase (MMP)-2 and MMP-
9, and tenascin-C also promote angiogenesis via regulation
of endothelial cell migration and invasion [11, 12]. It has
been previously shown that the Notch signaling pathway
has a critical role in vascular development [13]. Dll-4,
a membrane-bound ligand for Notch-1 and Notch-4 is
selectively expressed in some tumor endothelia, is induced
by VEGF and hypoxia and has been considered as a potential
therapeutic target [14].
However, the extensive preclinical studies have proved
inadequate to fully elucidate the mechanisms of action of
the anti-VEGF agents. Besides induction of endothelial cell
apoptosis and inhibition of new vessel formation, it is also
hypothesized that anti-VEGF agents may “normalize” the
tumor vessels by decreasing permeability and interstitial
pressure and thus reducing hypoxia and improving delivery
of cytotoxics, when given in combination [15, 16]. There is
clinical evidence of such normalization in patients who were
treated with bevacizumab for colorectal cancer or recurrent
glioblastoma and in recurrent glioblastoma patients treated
with cediranib, a novel pan-VEGF inhibitor (AZD2171,
Recentin) [17–19].
3.Bevacizumab
Bevacizumab (Avastin) has been the ﬁrst antiangiogenic
agenttogainapprovalforadministrationinrecurrentglioma
by FDA in May 2009. This humanized monoclonal antibody
targets VEGF and is already incorporated in the treatment of
colorectal, breast, lung, and kidney cancer.
The ﬁrst published trial with bevacizumab in recurrent
glioma was a single-arm phase II trial of bevacizumab
plus irinotecan that showed the encouraging results of 63%
radiologic response, 6-month PFS of 38%, and median PFS
of 23 weeks [20]. No CNS haemorrhages were reported,
but there were some thromboembolic events. This study
was followed by several others, trying to conﬁrm the
initial results. In a subsequent phase II trial of single-agent
bevacizumab for recurrent GBM, that included forty-eight
patients, a radiographic response of 35% and a 6-month
PFS of 29% were reported [21]. An important clinical eﬀect
of bevacizumab seen in this trial was the decrease of peritu-
moral edema that led to reductions in the required corticos-
teroid doses for a signiﬁcant proportion of the responding
patients, even including some that did not meet the PFS6
landmark. This observation has also been conﬁrmed in
other bevacizumab-treated patients [22] and it seems to
beacharacteristicpropertyofotherpotentanti-VEGFagents
like cediranib.
The previous experience with irinotecan in recurrent
gliomas had shown little activity of the agent, and this
raised the question of the irinotecan contribution to the
bevacizumab results [23, 24]. To investigate this, a phase II
trial randomized 167 patients with recurrent GBM to either
single-agent bevacizumab or bevacizumab with irinotecan.
The response rates were 28% and 38%, respectively, and PFS
at 6 months was 43% and 50% [25]. Median overall survival
was 9.2 and 8.7 months, conﬁrming again the minimal
impact of irinotecan to the results. Following these publica-
tions, the FDA granted accelerated approval for the use of
bevacizumab in recurrent disease, despite the lack of any
randomized data comparing bevacizumab monotherapy or
combination against a standard chemotherapy regimen.
Recently, the ﬁrst data of bevacizumab in the adjuvant
setting have become available [26]. In this phase II study
by Lai et al. seventy patients with newly diagnosed glioma
weretreatedwithstandardpostoperativechemoradiotherapy
plus biweekly bevacizumab. A control cohort of newly
diagnosed patients treated with ﬁrst-line RT and TMZ who
had mostly received BV at recurrence at the University of
California, Los Angeles/Kaiser Permanente was selected for
comparison. The overall survival (OS) and progression-
free survival (PFS) were 19.6 and 13.6 months, respectively,
compared to 21.1 and 7.6 months in the comparison group,
showing an improvement in the PFS but not in overall
survival. Subgroup analysis data indicate a potential beneﬁt
of upfront bevacizumab use for the poor prognosis patients,
emphasizing the need for further clinical investigation to
identify the optimal use setting.
4.Cediranib
Cediranib (AZD2171, Recentin) is an oral pan-VEGFR
tyrosine kinase inhibitor with additional activity against
platelet-derived growth factor β and c-Kit. It has a half-life
of 22 hours thus allowing once-daily dosing [27].
Based on preliminary data showing a potential beneﬁt
in patients with recurrent glioblastoma by normalization of
vasculature and alleviation of edema, a phase II study was
conducted including 31 patients with recurrent glioblastoma
[28]. They were all treated with cediranib 45mg/d p.o.,
and the primary endpoint was 6-month progression-free
survival. PFS-6 was 25.8%, and treatment was well tolerated.
Grade 3-4 toxicities included diarrhea, hypertension, and
fatigue. About half of the patients had entered the study
while on steroids, and the majority managed to reduce dose
or even discontinue their medication while on cediranib.
Changes in plasma placental growth factor, basic ﬁbroblast
growth factor, matrix metalloproteinase (MMP)-2, soluble
VEGF receptor 1, stromal cell-derived factor-1α, and sol-
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gelatinase-associated lipocalin activity after cediranib were
associated with radiographic response or survival, but their
value as predictive markers will require further exploring.
Disease progression during ongoing treatment with cedi-
ranib correlated with increases in bFGF, SDF1-alpha, and
viable circulating endothelial cells (CEC). Tumor progres-
sionafterdrugcessation,incontrast,correlatedwithincrease
in the number of circulating progenitor cells (CPC), suggest-
ing an independent role of CEC and CPC as biomarkers of
treatment response in patients treated with cediranib.
These promising results led to the design of a multicenter
three-arm phase III study (REGAL; NCT00777153) with
325 patients, where cediranib alone and combination with
lomustineweretestedversuslomustinealoneinpatientswith
recurrent glioblastoma [29]. PFS at 6 months (PFS-6) was
16% in the monotherapy arm compared with 34.5% in the
combination arm and 24.5% in the control arm, and no
signiﬁcant diﬀerence has been identiﬁed. Therefore, cedi-
ranib alone or the addition of cediranib to lomustine did not
improve PFS in comparison to lomustine alone. The PFS-6
of 16% in the cediranib arm was lower than the PFS-6 of
25.8% reported in the previous phase II trial. Possibly, the
diﬀerent doses of cediranib used in the two trials, that is,
45mg in the phase II versus 30mg in the monotherapy and
20mg in the combination arm of the phase III trial, may
indicate a dose-response property which could be the ex-
planation for the diﬀerence in the PFS-6 seen in the two
studies.
Currently cediranib is under investigation in paediatric
patients with recurrent CNS tumors and in several adult
studies. There is an ongoing phase I trial of the combination
with gamma-secretase/Notch signalling pathway inhibitor
RO4929097 in solid tumors. The addition of geﬁtinib versus
placebo to cediranib is explored in a randomized phase II
study in recurrent glioma, while another phase II is eval-
uating the addition of cediranib versus placebo to chemora-
diotherapy in newly diagnosed glioblastoma. Cediranib
plus the triple angiokinase inhibitor BIBF1120 in recurrent
glioblastoma is tested in a phase II safety and eﬃcacy study
and ﬁnally cediranib and cilengitide, which targets the ανβ3
andανβ5integrinreceptorsarecombinedinaphaseIbstudy
in a recurrent glioblastoma patient population [30].
5. Cilengitide(EMD121974)
Cilengitide is a cyclized arginine-glycine-aspartic acid-
containingpentapeptidethatselectivelybindsthecellsurface
receptors ανβ3 and ανβ5, which are expressed on activated
endothelial cells during angiogenesis [31]. It can also act
directlyonανβ3-andανβ5-expressingtumorcellsandinhibit
important signals involved in survival and growth and indi-
rectly by inhibiting angiogenesis and thereby tumor growth
[32]. In glioblastoma, both activated endothelial cells and
tumor cells express the target integrins of cilengitide [33].
Cilengitide has been the ﬁrst integrin-receptor antagonist to
enter clinical development. Data from phase I studies have
shown activity in recurrent glioblastoma [34], and a phase
II study where 81 patients were randomized to single-agent
cilengitide 500mg or 2000mg iv. twice weekly until pro-
gression has oﬀered evidence of good tolerance and modest
activity in both arms, with a trend favoring the 2000mg
dose. PFS-6 was 15%, and OS was 9.9 months [35]. These
results together with preclinical data supporting a synergistic
eﬀect between cilengitide and radiotherapy [36]p r o v i d e d
the rationale to combine this agent with chemoradiotherapy
in newly diagnosed glioblastoma. In this phase I/IIa study,
52 patients were treated with cilengitide 500mg iv. twice
weekly in addition to standard chemoradiotherapy with
temozolomide until progression or up to 35 weeks [37].
Primary endpoint was 6-month PFS. Six- and 12-month PFS
rates were 69% and 33%, and median PFS and OS were
8 and 16.1 months, respectively. PFS and OS were longer in
patients with tumors with O6-methylguanine-DNA methyl-
transferase (MGMT) promoter methylation (13.4 and 23.2
months)versusthosewithoutMGMTpromotermethylation
(3.4 and 13.1 months). The reasons for this ﬁnding remain
unclear. No synergistic eﬀects were identiﬁed for the combi-
nationofcilengitideandTMZinvitro,andtheMGMTstatus
hadnoeﬀectonthebiologicactivityofcilengitide.Apossible
explanation could be that the cilengitide-induced vascular
normalizationimprovesthedeliveryofTMZtotumortissue,
especially in patients with MGMT promoter methylation
[31].
Currently, cilengitide is being evaluated in a recently
completed pivotal, randomized Phase III study (Cilengitide
in Combination with Temozolomide and Radiotherapy in
Newly Diagnosed Glioblastoma Phase III Randomized Clin-
ical Trial (CENTRIC)) for newly diagnosed Glioblastoma
Multiforme with MGMT promoter methylation [38]. Fol-
lowing this trial, a similar one has been designed for patients
with unmethylated tumors [39] and their results are eagerly
awaited. The combination of cilengitide with sunitinib
malate is tested in a pilot biomarker study and chemoradio-
therapy with cilengitide or cetuximab are being investigated
in a randomized, noncomparative trial in patients with
newly diagnosed MGMT-promoter unmethylated glioblas-
toma (CeCil) [40].
6.Sunitinib
Sunitinib is a multityrosine kinase inhibitor which tar-
gets PDGFR, vascular endothelial growth factor receptor-
2 (VEGFR-2), and the proto-oncogenes RET, KIT, FLT3,
and CSF-1. It is FDA-approved as ﬁrst-line treatment for
advanced renal cell carcinoma, hepatocellular carcinoma,
and progressive gastrointestinal stromal tumors (GIST) re-
sistant to imatinib. It has also been reported to have activity
inrenalcellcarcinomaCNSmetastases[41].Theimplication
thatsunitinibmaycrosstheblood-brainbarrierhasprovided
the basis for designing trials to explore its activity in brain
tumors.
An in vitro study in glioma cell lines showed some inter-
esting results regarding the eﬀect of sunitinib in response
to temozolomide and radiotherapy. They have demonstrat-
ed that adding sunitinib to chemoradiotherapy increased4 Chemotherapy Research and Practice
sensitivity of the O(6)-methylguanine-methyltransferase-
(MGMT-) positive cells, but did not aﬀect the MGMT-
negative ones. MGMT-positive cells displayed higher levels
of vascular endothelial growth factor receptor 1 (VEGFR-
1) whereas the negative ones displayed decreased levels of
VEGFR-2. Also, they showed that MGMT expression was
associated with a signiﬁcant increase in the soluble VEGFR-
1/VEGFA ratio, thereby suggesting a decrease in bioactive
VEGFA and a shift towards an antiangiogenic proﬁle. This
direct correlation between MGMT and reduced angiogenic-
ity and tumorigenicity may suggest a role for sunitinib in
combination with standard treatment in MGMT-positive
gliomas [42].
In another preclinical study in a mouse tumor model,
sequential administration of sunitinib and temozolomide
suggested a dose-dependent action of sunitinib on tumor
penetration of temozolomide [43].
However, the available clinical data have been less
optimisticandsunitinibhasnotyetdemonstratedsigniﬁcant
activityinthepublishedtrials.InaphaseIIstudy,itwasgiven
as single agent on recurrence following chemoradiotherapy
at a dose of 37.5mg/day and MRI was used to evaluate the
antiangiogenic eﬀects of sunitinib. There were no objective
responses, and median time to progression and overall
survival were 1.6 and 3.8 months, respectively [44].
The combination of sunitinib and irinotecan in a phase
I study, where the MTD for sunitinib was 50mg/day for 4
weeks on a 6-week cycle with Irinotecan at 75mg/m2 every
other week, had moderate toxicity but minimal activity [45].
Currently sunitinib is being tested in two phase II trials, one
for recurrent anaplastic astrocytoma and glioblastoma and
one for inoperable newly diagnosed glioblastoma before and
during radiotherapy [46].
7. Sorafenib
Sorafenib is an oral VEGFR-2, Raf, PDGFR, c-KIT, and Flt-3
inhibitor currently approved for renal cell and hepatocellular
carcinomas, which is also under evaluation for lung and
breast cancer. Preclinical data suggest that sorafenib inhibits
STAT-3 signalling and therefore contributes to growth arrest
and induction of apoptosis in glioblastoma cells. These
ﬁndings could provide a rationale for potential treatment of
malignant gliomas with Sorafenib [47].
The addition of Sorafenib 400mg twice daily to temo-
zolomide in the maintenance period of treatment in newly
diagnosed glioblastoma following standard chemoradiother-
apy was investigated in a phase II study with 47 patients. 19
withdrew before initiation of maintenance treatment due to
progression and only 9 received 6 months of treatment as
planned. Median PFS was 6 months, and 1-year PFS was
16%. Median overall survival was 12 months. Maintenance
treatmentwithsorafenibwaswelltoleratedwithnograde3/4
toxicities, but it did not seem to add to the standard treat-
ment eﬀect [48].
Sorafenib is being evaluated in a phase I/II trial in com-
bination with temsirolimus in recurrent glioblastoma and in
a phase I trial in combination with standard chemoradio-
therapy and maintenance temozolomide in newly diagnosed
patients [49].
8.Vandetanib
Vandetanib (ZD 6474) is a VEGF and EGF receptor tyrosine
kinase inhibitor. The VEGF receptors, VEGFR-1 (ﬂt-1) and
VEGFR-2 (KDR), are commonly present on endothelial cells
and have also been identiﬁed in human glioblastoma cells.
In addition, EGFR is dysregulated in the majority of human
glioblastomas and EGFR overexpression correlates with
shorter survival. The eﬀect of vandetanib as a dual inhibitor
of VEGF and EGFR signaling has been studied as single
agent and in combination with radiation. Preclinical data
have shown that irradiation of glioblastoma xenografts in
combination with vandetanib signiﬁcantly increased tumor
doubling time compared with RT alone. The growth delay
correlated with suppression of pAkt, survivin, and Ki67
expression in tumor samples. The presence of EGFR aug-
mentedRT-stimulatedVEGFrelease;thiseﬀectwasinhibited
byvandetanib.Inthisstudythatalsoincludedcediranib,nei-
ther TKI aﬀected clonogenic cell survival following RT nor
GBM xenografts expressing EGFR exhibited greater sensitiv-
ity to both cediranib and vandetanib than EGFR-null tumors
[50]. In a similar setting, Damiano et al. have shown that
when irradiation and vandetanib are applied to glioma xen-
ografts and cell lines, they cause a longer-lasting inhibition
of tumor growth and vessel formation, as compared to
the reversible inhibition produced by each compound given
separately [51].
Another in vitro study evaluated the eﬀect of vandetanib
on the blood-brain barrier (BBB) and the potential detri-
mental eﬀect of that on chemotherapy activity. They have
used glioblastoma xenografts in mice, that were treated with
vandetanib, temozolomide, or both. Vandetanib selectively
inhibited angiogenic growth aspects of glioma and restored
the BBB. It did not notably aﬀect diﬀuse inﬁltrative growth
and survival. Also, vandetanib antagonized the eﬀects of
temozolomide, presumably by restoration of the BBB and
obstruction of chemodistribution to tumor cells [52]. These
results generate a whole set of questions regarding the
eﬃcacy of the concomitant use of antiangiogenic agents with
chemotherapy in brain tumors.
Vandetanib was tested in a phase I study in combination
withtemozolomideandRTinnewlydiagnosedglioblastoma.
The maximum dose administered was 200mg daily and the
toxicities included gastrointestinal bleeding and perforation,
neutropenia,andthrombocytopenia[53].Vandetanibisnow
evaluated in an ongoing phase II study, where it is given with
temozolomide and RT at the dose of 100mg daily.
9. ABT-510/Thrombospondin-1 (TSP-1)
TSP-1 is a 450-kD homotrimeric extracellular matrix glyco-
protein. It has a complex structure and modulates cellular
motility, adhesion, and proliferation, functions that are all
important for tumor growth and metastasis [54]. TSP-
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endothelialcellproliferation,migration,andcordformation,
both in vitro and in vivo [55, 56]. Both intact TSP-1 and
derived peptides have been shown to induce apoptosis in
endothelial cells [57]. The in vitro antiangiogenic activity
of TSP-1 is mediated by the CD36 receptor expressed on
endothelial cells [58]. TSP-1 production by glioma cells is
reduced under hypoxic conditions, while VEGF is increased,
causing an imbalance that favors angiogenesis. Tenan et al.
showed that increased expression of TSP-1 by two- to 28-
fold suppresses tumorigenicity of glioblastoma cells in an
animal model, which indicates that even a modest reduction
in TSP-1 production might be relevant to human tumor
progression [59]. In a very interesting in vitro study, Filleur
et al. demonstrated a potential explanation on how tumors
canovercomeTSP-1activityandrestoreangiogenesisdespite
high levels of TSP-1 expression, thus developing acquired
resistance to antiangiogenic drugs [60].
ABT-510isaTSP-1mimeticantiangiogenicdrugthathas
been tested in newly diagnosed glioblastoma on a phase I
trial concurrently with temozolomide and RT. Subcutaneous
injections of 20–200mg were used and there were no
dose-limiting toxicities identiﬁed. The study included gene
expression analysis, using TaqMan low-density arrays to
identify angiogenic genes that were diﬀerentially expressed
in the brains of controls, compared with patients with newly
diagnosed glioblastoma. FGF-1 and TIE-1 genes were found
to be downregulated in patients who had better clinical
outcomes [61].
10. XL184
XL-184 (BMS-907351) is a pan-tyrosine kinase inhibitor for
the potential oral treatment of medullary thyroid cancer,
glioblastoma multiforme, and NSCLC. The principal targets
of XL-184 are MET, VEGFR-2, and RET, but the drug is also
reported to display inhibitory activity against KIT, FLT3, and
TEK. Also, it is known that elevated MEK and KIT correlate
with poor prognosis. Preclinical studies demonstrated that
XL-184 potently inhibited multiple receptor tyrosine kinases
in various cancer cell lines and animal xenograft models.
Phase I data indicated that XL-184 accumulated dose depen-
dentlyintheplasmaandhadalongterminalhalf-life.Results
from a phase II study in glioblastoma on ﬁrst or second
relapse showed that the drug is active and can produce
responses at the dose of 175mgPOqd, in a group of patients
who had previously been treated with antiangiogenic agents.
However, toxicity had been an issue in this trial, as 52% of
the 46 enrolled patients interrupted or stopped treatment
becauseofanadverseevent[62].Theseincludedmyocarditis,
troponinelevation,pulmonaryembolism,CNShemorrhage,
nausea, fatigue, and dehydration. A second cohort was
added subsequently, that received a dose of 125mg. In
the 175mgqd cohort (n = 46), PFS6 (all pts) was 21%
and median duration of response was 5.9 months. Most
frequent Gr3/4 AEs were fatigue (23%), hypophosphatemia
(10%), serum lipase elevation (10%) and ALT, headache,
lymphopenia, and convulsion (9% each), with similar eﬀect
on both dose levels [63]. Currently, there are two ongoing
phase II trials with XL184, studying the administration as
single agent in astrocytoma and glioblastoma, respectively
and a phase I safety study that evaluates incorporation of
XL184 in the standard chemoradiation program for newly
diagnosed glioblastoma, giant cell glioblastoma, and gliosar-
coma [64].
11.VEGFTrap/Aﬂibercept
VEGF Trap/aﬂibercept has been developed by incorporating
domains of both VEGF receptor 1 (VEGFR-1) and VEGFR-
2 fused to the constant region of human immunoglobulin
G1, which acts as a soluble decoy receptor for VEGF. It is
known to have very high aﬃn i t yf o ra l li s o f o r m so fV E G F - A
(<1pM), as well as placental growth factor, a closely related
angiogenic factor [65]. Its eﬃcacy has been proven in several
preclinical studies of solid tumors and in a subcutaneous
glioma model [66–68]. In a preclinical study with ani-
mals bearing intracranial glioma xenografts, it produced
i m p r o v e ds u r v i v a lw h e ng i v e ni nap r o l o n g e ds c h e d u l ea n d
maintained its eﬃcacy both in early-stage and advanced
disease [69]. Until now, there has been one phase II trial in
glioma at ﬁrst relapse that is pending publication and a new
phase I trial not opened yet, where VEGF Trap is applied
together with standard chemoradiotherapy with temozolo-
mide in untreated patients [70].
12. Tandutinib
Tandutinib (MLN518) is a 4-piperazinyl quinazoline com-
pound that is a potent inhibitor of type III receptor tyrosine
kinases (RTKs) including PDGFR-β, FLT-3, and c-Kit. It has
been extensively studied in the context of acute myeloid
leukemia in combination with approved drugs and showed
signiﬁcantactivityandsynergisticproperties[71].Ithasbeen
tested in glioma patients in a feasibility and phase I study
at doses from 500 to 700mgbid. The observed toxicities
included fatigue, somnolence, and phosphorus disorders,
and the recommended dose for phase II was set at 600mg.
There are currently two ongoing tandutinib studies in
glioma, one phase II in relapsed disease in combination with
bevacizumab and one feasibility and phase I/II trial in
relapse after radiotherapy with or without chemotherapy, to
establish maximum dose and pharmacokinetic proﬁle [72].
13. Conclusions
Management of glioblastoma remains a challenging area in
oncology. The current approved treatments oﬀer survival
rates that are far from satisfactory, and clinical research is
intensively trying to identify more eﬀective agents to incor-
porate in clinical use. The particular pathologic and molec-
ular features that characterize glioblastoma and regulate its
clinical course are currently investigated in conjunction with
n e wt a r g e t e da g e n t sw h i c h ,i fp r o v e ne ﬃcient, might give the
answers so eagerly awaited. Angiogenesis undoubtedly plays
a critical role in the development and survival of glioblas-
toma; it is therefore expected that the antiangiogenic drugs6 Chemotherapy Research and Practice
will remain key players in the treatment design. It is ques-
tionable, though, whether we have suﬃciently understood
their eﬀects in the tumor environment, their interaction
with chemotherapy agents, and their mode of application
that can lead to optimum results.
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